Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Caveat Emptor When Buying High-Yield Drug Stocks


Caveat Emptor When Buying High-Yield Drug Stocks

Income investors seemingly have hundreds of stocks to choose from that currently pay a dividend. The telecom and utility sectors often generate some of the most robust payouts for investors, with FactSet Research data from the third quarter of 2016 showing that sector aggregate yield for telecom was double that of the S&P 500 (4%, versus 2%).

By comparison, the healthcare sector is a major disappointment to income investors, with an average yield of about 1.8%.  Scratching the surface, drug stocks would appear to be the perfect candidates to pay out a substantial yield given their exceptional pricing power, and the fact that they sell inelastic products. In other words, people can't control when they get sick or what ailment they contract, meaning demand for medicine isn't dependent on how well or poorly the U.S. economy is performing. But the data shows that drug stocks are often far from perfect dividend stocks.

Image source: Getty Images.

Continue reading


Source: Fool.com

GSK plc ADR Aktie

40,80 €
-0,48 %
Die GSK plc ADR Aktie notiert heute etwas tiefer, mit einem Rückgang von -0,48 %.

Like: 0
GSK
Teilen

Kommentare